valproic acid has been researched along with Deficiency, Vitamin B in 6 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carnitine treatment does not always prevent the emergence of serious hepatotoxicity, but it does alleviate valproate-induced hyperammonemia." | 6.39 | Carnitine deficiency in epilepsy: Risk factors and treatment. ( Coulter, DL, 1995) |
| " Hyperhomocysteinemia was defined as fasting total Hcy above 12 micromol/L and/or post-methionine load concentrations above 38 micromol/L." | 3.74 | Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins. ( Apeland, T; Frøyland, ES; Kristensen, O; Mansoor, MA; Strandjord, RE, 2008) |
| "Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well tolerated, but rare serious complications may occur in some patients receiving VPA chronically, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity (VHT) and VPA-induced hyperammonaemic encephalopathy (VHE)." | 2.43 | Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? ( Gris, M; Lheureux, PE; Penaloza, A; Zahir, S, 2005) |
| "Carnitine treatment does not always prevent the emergence of serious hepatotoxicity, but it does alleviate valproate-induced hyperammonemia." | 2.39 | Carnitine deficiency in epilepsy: Risk factors and treatment. ( Coulter, DL, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ono, H | 2 |
| Apeland, T | 1 |
| Frøyland, ES | 1 |
| Kristensen, O | 1 |
| Strandjord, RE | 1 |
| Mansoor, MA | 1 |
| Kasturi, L | 1 |
| Sawant, SP | 1 |
| Lheureux, PE | 1 |
| Penaloza, A | 1 |
| Zahir, S | 1 |
| Gris, M | 1 |
| Coulter, DL | 1 |
2 reviews available for valproic acid and Deficiency, Vitamin B
| Article | Year |
|---|---|
Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?
Topics: Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Drug Overdose; Hepatic Encephalo | 2005 |
Carnitine deficiency in epilepsy: Risk factors and treatment.
Topics: Carnitine; Epilepsy; Humans; Liver; Risk Factors; Valproic Acid; Vitamin B Deficiency | 1995 |
4 other studies available for valproic acid and Deficiency, Vitamin B
| Article | Year |
|---|---|
Sodium valproate-induced Fanconi syndrome in two severely disabled patients receiving carnitine supplementation.
Topics: Adult; Anticonvulsants; Carnitine; Disabled Persons; Epilepsy; Fanconi Syndrome; Female; Humans; Int | 2019 |
Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Cysteine; Dipeptides; Drug Evaluation; | 2008 |
Sodium valproate -- induced skeletal myopathy.
Topics: Anticonvulsants; Carbamazepine; Carnitine; Child, Preschool; Epilepsy; Humans; Male; Muscular Diseas | 2005 |
[A severe disabled case of incomplete Fanconi syndrome after discontinuation of carnitine supplementation during valproate sodium therapy].
Topics: Anticonvulsants; Carnitine; Child; Disabled Children; Fanconi Syndrome; Female; Humans; Valproic Aci | 2007 |